| Cellular Therapy: Targets and Effectors | |
| Adoptive Immunotherapy in Chimeras | p. 3 |
| The Roles of the Chemokine SDF-1 and its Receptor CXCR4 in Human Stem Cell Migration and Repopulation of NOD/SCID and B2mnull NOD/SCID mice | p. 11 |
| Towards Adoptive Immunotherapy Using High Affinity T Cell Receptors | p. 25 |
| New Antigens and Avenues to Immunotherapy of Cancer | p. 29 |
| Allogeneic Cell Therapy with Antigen-Specific Cytotoxic T Lymphocytes (CTL) for Malignant Melanoma | p. 37 |
| New Conditioning Strategies in Allogeneic Stem Cell Transplantation | |
| Intensification of the Conditioning Regimen for Patients with high-risk AML and MDS: 3 year Experience of using an 188Re - Labelled anti - CD 66 Monoclonal Antibody | p. 43 |
| Dose Reduced Conditioning for Allogeneic Blood Stem Cell Transplantation from Sibling and Unrelated Donors in 51 Patients | p. 59 |
| Pharmacokinetics of Conditioning Regimens | p. 74 |
| Megadose Stem Cell Transplantation | p. 79 |
| HD-Ara-C in the Conditioning Regimen for BMT in Acute Leukemias | p. 84 |
| TBI-Based Reduced Intensity Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation (SCT) in Patients with High-Risk Hematologic Malignancies | p. 91 |
| Total Marrow Irradation (TMI), Busulfan, and Cyclophos-phamide for Allografting in Multiple Myeloma. A Pilot Study | p. 95 |
| Stem Cell Mobilisation, Processing and Characteristics | |
| A "Single" Delayed Application of G-CSF after Autologous Peripheral Blood Stem Cell Transplantation - A Pilot Study | p. 107 |
| Factors Influencing PBPC Mobilisation and Collection in Haematological Malignancies | p. 111 |
| Successful Purging of Stem Cell Products Using CD34 Selection | p. 116 |
| Autologous Transplantation of Non-Cryopreserved HSCs in Oncologic Patients with Poor Prognosis: First Experience in the Ukraine | p. 130 |
| A Randomized Comparison of Once Versus Twice Daily rhG-CSF (Filgrastim) for Stem Cell Mobilisation in Healthy Donors for Allogeneic Transplantation | p. 138 |
| CD 133/CD34 Expression on Hematopoietic Stem-/Progenitor Cells and Acute Leukemic Blasts | p. 145 |
| Identification of Minimal Residual Leukemia Applying Continuous Gating | p. 156 |
| Cord Blood Transplantation | |
| Pilot Study - Lymphocyte Subset Reconstitution after Cord Blood Transplantation | p. 167 |
| Altered Growth Characteristics of Cord Blood afterin vivo Exposure of the Mother to Chemotherapy | p. 177 |
| Mismatched Donor Transplantation | |
| Bone Marrow Transplantation from Mismatched Unrelated Donors | p. 183 |
| Immune Reconstitution after Haploidentical Stem Cell Transplantation | p. 190 |
| Clinical Transplantation - Hematologic Malignancies | |
| Autografting and Allografting for Chronic Lymphocytic Leukemia: Is there a Rationale? | p. 197 |
| Results of Stem Cell Transplantation in Children with CML in Comparison with Treatment with Cytostatics alone or with Interferon alfa. Report of the Polish Children's Leukemia/Lymphoma Study Group | p. 205 |
| Comparison of Allogeneic Matched Related Stem Cell Transplantation in 1st CR with Chemotherapy alone in Children with High-Risk AML | p. 210 |
| Stem Cell Transplantation in Acute Myeloid Leukemia after Conditioning with Busulfan, Cyclophosphamide and Different Dosages of Etoposide (VP-16) | p. 219 |
| The Occurrence of Acute Graft-Versus-Host Disease and Infectious Complications in Patients with Acute and Chronic Myeloid Leukemia who Underwent Allogeneic PeripheralBlood Stem Cell Transplantation | p. 228 |
| Long-Term Survival after Stem Cell Transplant in Adult Acute Lymphoblastic Leukemia | p. 233 |
| Clinical Transplantation - Solid Tumors Autologous Transplantation in Breast Cancer in Europe and EBMT Data | p. 245 |
| First-Line and Salvage High-Dose Chemotherapy in Patients with Germ-Cell Tumors | p. 253 |
| High Dose Chemotherapy in High-Risk Ewing Tumours: Results in 156 (EI)CESS Patients | p. 263 |
| Rapid Sequence Tandem Transplant in Children with High-Risk Neuroblastoma | p. 270 |
| Anti-Angiogenesis | |
| Angiogenesis Inhibitor TNP-470 During Bone Marrow Transplant and in Minimal Residual Disease | p. 283 |
| Challenges in the Treatment of Fungal Infections Prophylaxis of Fungal Infections in Neutropenic Patients with Hematologic Malignancies | p. 301 |
| Subject Index | p. 309 |
| Table of Contents provided by Publisher. All Rights Reserved. |